Last reviewed · How we verify
NCT07267091
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
trial testing No Intervention: Observational Cohort in Lupus in 88 participants. Completed in 23 January 2026.
23 January 2026
Quick facts
| Lead sponsor | PeriPharm |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 3 November 2025 |
| Primary completion | 23 January 2026 |
| Estimated completion | 23 January 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- No Intervention: Observational Cohort — full drug profile →
Conditions studied
- Lupus — all drugs for Lupus →
- Lupus Arthritis — all drugs for Lupus Arthritis →
- Lupus Arthritis, Systemic Lupus Erythematosus — all drugs for Lupus Arthritis, Systemic Lupus Erythematosus →
- Quality of Life (QOL) — all drugs for Quality of Life (QOL) →
Sponsor
PeriPharm
Who can join
18 and older, any sex, with Lupus or Lupus Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to capture the Canadian patient experience, burden, barriers, and treatment preferences. The findings will generate real-world evidence to support patient-centered care and guide healthcare providers, researchers, and decision-makers in improving support and treatment for people living with lupus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07267091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention: Observational Cohort
Trials testing the same drug.
- NCT07284771 — MUSCLE-ML: Multimodal Integration of Muscle Strength, Structure by Machine Learning for Precision Rehabilitation After A · not yet recruiting
- NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07475468 — CP382 - Intermittent Catheter (IC) PRO Panel Plan · not yet recruiting
- NCT07382570 — Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months · not yet recruiting
Other recruiting trials for Lupus
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07282392 — Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET) · NA · recruiting
- NCT06839976 — CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus · Phase 1, PHASE2 · recruiting
- NCT06434363 — Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di · Phase 1, PHASE2 · recruiting
- NCT06013995 — A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With D · Phase 1 · recruiting
Other PeriPharm trials
Trials by the same sponsor.
- NCT07035067 — Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada · terminated
- NCT06610045 — The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study · completed
- NCT05556564 — The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study · completed
- NCT03640650 — Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study. · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07267091 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PeriPharm
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07267091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing